In vivo and in vitro anti-inflammatory and anti-nociceptive activities of lovastatin in rodents. D.O. Gonçalves, I.B.F. Calou, R.P. Siqueira, A.A. Lopes, L.K.A. Leal, G.A.C. Brito, A.R. Tomé and G.S.B. Viana.
Figure 4. Effects of lovastatin (LOV) on the release of human neutrophil myeloperoxidase (MPO) stimulated with phorbol myristate acetate (PMA). The cells were pre-incubated with LOV (0.01, 0.1 and 1 μg/mL) or indomethacin (INDO, 35.7 μg/mL) as the reference drug, prior to the addition of PMA. The suspension was centrifuged (10 min at 2000 g, 4°C). Supernatant aliquots (50 μL) were added to PBS (100 µL), phosphate buffer (50 µL, pH 7.0) and H2O2 (0.012%). After 5 min at 37°C, the substrate 3,3’,5,5’-tetramethylbenzidine (TMB, 1.5 mM, 20 µL) was added, the reaction stopped with 1.5 M sodium acetate, pH 3.0, and absorbance determined at 620 nm. Data are reported as percent inhibition of MPO release (mean ± SEM).